Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Announces Participation in March Investor Conferences

Monday, February 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax Pharmaceuticals announced its participation in upcoming investor conferences, featuring CEO Michael A. Metzger and the management team. The company will provide live webcasts of the events on its website. Syndax is known for its innovative cancer therapies, including FDA-approved treatments like Revuforj and Niktimvo.
Price reaction · baseline $19.69 (2026-02-20 close) · hit pre-market · 1 other SNDX headline(s) in the window, move may be shared
day 0 close · peak
+1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax is actively participating in investor conferences, showcasing engagement.
  • The company has FDA-approved therapies, indicating strong product validation.
  • Syndax is committed to advancing innovative cancer therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
A live webcast of the fireside chats will be available in the Investor section of the Company's website atwww.syndax.com, where a replay will also be available for a limited time.
About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.com/or follow the Company onXandLinkedIn.

Syndax Contacts

Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827
SNDX-G

Frequently Asked Questions

Who will represent Syndax at the investor conferences?

CEO Michael A. Metzger and the Syndax management team will represent the company.

Where can I watch the live webcasts?

The live webcasts will be available in the Investor section of Syndax's website.

What are some of Syndax's FDA-approved therapies?

Syndax's FDA-approved therapies include Revuforj and Niktimvo.

What is the focus of Syndax Pharmaceuticals?

Syndax focuses on advancing innovative cancer therapies.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Syndax Pharmaceuticals investor conferences FDA-approved therapies cancer treatments
Last updated: Feb 23, 2026

Biotech snapshot

Cash runway
$548M liquidity · $10M/mo burn
~54 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →